AqVida to bring News of New Development Projects to CPhI Worldwide Forum

Press Release – AqVida GmbH
AqVida to bring News of New Development Projects to CPhI Worldwide Forum

AqVida Logo

Contact Supplier: AqVida GmbH
Supplier Press Release: AqVida to bring News of New Development Projects to CPhI Worldwide Forum
Address: Kaiser-Wilhelm-Str.89, 20355 Hamburg, Germany
Tel: +49 40 380 37190
Fax: +49 40 380 37192
Website: www.aqvida.com

OCTOBER 11, 2013

AqVida to bring News of New Development Projects to CPhI Worldwide Forum

Hamburg, Germany: – German oncology specialist, AqVida, will present exciting new development projects as well as an expanded product portfolio when it attends the forthcoming CPHI Worldwide Pharma Expo in Frankfurt on October 22-24.

In the past AqVida has been a regular visitor to the Forum however this year due to CPhI taking place in AqVida’s home country AqVida are pleased to announce for the first time they will be an exhibitor at the show.

“As a German pharmaceutical company, CPhI is a key forum for us,” said AqVida’s CEO, Wolfgang Heinze. “We come to Frankfurt Messe to emphasize our standing as an upcoming manufacturer and respected specialist in oncology-related products and as experts in regulatory compliance in international markets.”

CPhI brings together over 30,000 attendees from 140 countries, along with 2,200 exhibitors.

Proven Products
“CPhI is also the place where we can meet existing and potential partners to update them on the many exciting developments we have in our pipeline for 2014, particularly for pharmaceutical industry clients interested in licensing oncology products that are proven effective,” said Mr. Heinze.

AqVida will also be present at Stand F0D12NEP at the CPhI Worldwide Exhibition, where its team will be able to provide details of exciting new projects including Pemetrexed, Erlotinib and Sunitinib development.

The AqVida exhibition will focus on the importance of high product quality and the necessity to ensure that all manufacturing, analysis and distribution processes are EU-GMP certified to meet the high quality standards of the European market.

“This has been the key to the success of core products such as Oxaliplatin, Paclitaxel, Docetaxel, and Imatinib that are not only licensed across Europe but also international markets that value German product quality,” said Wolfgang Heinze.

AqVida is inviting potential collaborators to contact the company directly.

About AqVida
AqVida is a German pharmaceutical company specializing in the development, registration and distribution of finished dosage forms mainly in the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.

AqVida’s expertise in the development, registration and supply of generic oncology products and biosimilars has made the company a well established partner in the pharmaceutical industry. The Hamburg-based company also has offices in Oberhaching, Bavaria and in Hangzhou, China.

AqVida works alongside some of the major companies in the market of oncology products. Together with its partners AqVida has achieved substantial development and growth with its oncology portfolio.

As a pharmaceutical company AqVida fulfils all your requirements from API sourcing up to EU market release for the finished product. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.

AqVida also produces Active Pharmaceutical Ingredients (APIs) with all required compliance documentation as well as full supply chain qualification. Products are sold under the AqVida brand or those of its partners’ in the EU and other markets.

AqVida complies with all German and EU legal requirements for the pharmaceutical industry including, EU-GMP, AMG and AMWHV and is also GMP certified by the German Health Authorities. As a European organisation, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market. The company is also able to assist manufacturers outside the EU wishing to enter the European market.

About CPhI
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors’ opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends. It is staged by UBM Live, the leading Global B2B Events Organisers and Publishers.

Now in its 24th year, the 2013 event is being held from October 22-24 at Messe Frankfurt and will host more than 30,000 delegates from 140 countries along with 2,200 exhibitor companies.

The CPhI Worldwide ingredients and manufacturing show is being held alongside three other zoned exhibitions; InnoPack packaging, ICSE Outsourcing solutions and P-MEC Machinery and Equipment.

The Pre-Connect Conference on October 21 comprises six modules on current industry ‘hot topics’ and offers themed networking opportunities.

Contact:
AqVida GmbH
Tel: +49 40 380 37190
Email: info@aqvida.com

For more information about AqVida attending CPhI, please contact AqVida directly.

Comments are closed.